ADHD Drug Causing Suicides and Liver Failure Warns FDA

by | Aug 11, 2009


A green chalkboard with the message 'I LOVE YOU' written in white chalk.The FDA continues to receive reports that the ADHD drug Strattera (atomoxetine), is causing serious liver injury and deaths, in spite of the BOLD TYPE WARNING in the drug insert. Strattera, which is manufactured by Eli Lilly & Co, was approved by the FDA for ADHD in November 2002, for adults and children aged 6 years and above.


The Strattera label does have a BLACK BOX WARNING about the increased risk of SUICIDE in adolescents and children taking the drug. Unfortunately, this does not seem to deter doctors from prescribing it to unaware or uniformed parents who are frequently pressured by teachers to put their kids on the drugs. Between 2002 and 2007, about 3.3 million people were prescribed Strattera, and over 2 million were children under 18 years old.


Drug induced liver injury is the most common reason for acute liver failure in the United States. A drug may cause chemical damage to liver cells which can result in serious injury to the liver and may cause death. Signs of liver damage include nausea, jaundice, vomiting, bleeding, abdominal pain or mental confusion. Kidney failure may also be present in some cases.


In 2004 the warning label for Strattera was updated to indicate that it could cause severe liver injury, which may progress to liver failure resulting in death or the need for a liver transplant in a small number of patients.


However, as with most drugs, as long as Strattera cannot be definitely linked to more than 100 deaths, the FDA will most likely leave it on the market and simply recommend that healthcare providers and patients taking it watch for symptoms of depondency, depression, nausea, jaundice, vomiting, bleeding, abdominal pain or mental confusion, or death, which could be signs of liver toxicity or kidney failure.


Perhaps, on the other hand, any drug with a BOLD TYPE WARNING or a BLACK BOX WARNING, SHOULD BE AVOIDED LIKE THE BLACK PLAGUE, ARSENIC, OR A 3 ALARM FIRE.


 
Dr. Hansen simply says “Don’t do drugs!†There are safe and effective natural alternatives to Straterra, Ritalin, Adderall, Cylert, and all the others.


For more information about ADHD and the natural alternatives, click here.

Ivermectin + Mebendazole taken together produce remarkably Positive Clinical Cancer Benefits in 84.4% of Patients.

The largest real-world human analysis to date evaluating ivermectin and mebendazole in cancer patients has just been published—and the results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

This groundbreaking analysis was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel (Dr. Harvey Risch)—uniting real-world clinical data, frontline medical experience, and high-level epidemiologic expertise to deliver urgently needed insights in oncology.

This was a real-world prospective clinical program evaluation of 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

Cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

The cohort represented a clinically relevant population, including a wide variety cancer types, with 37.1% of patients reporting actively progressing disease at baseline and many having already undergone chemotherapy, radiation, and surgery.

At six months, 84.4% of cancer patients reported clinical benefit (Clinical Benefit Ratio: 84.4% [95% CI: 77.0–89.8%]):

✅ 32.8% reported NO evidence of cancer (95% CI: 25.1–41.5%)
✅ 15.6% reported tumor regression (95% CI: 10.2–23.0%)
✅ 36.1% reported stable disease (95% CI: 28.1–44.9%)

Treatment adherence was high, with 86.9% completing the full protocol and 66.4% remaining on therapy at six months.

The regimen was well tolerated, with 25.4% reporting side effects, primarily mild and gastrointestinal, and over 93% continuing treatment despite these events.

Patients were treated in real-world conditions alongside concurrent therapies, including chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%), supporting use as an adjunctive approach.

Together, these findings represent a large, internally consistent real-world clinical signal that supports URGENT further investigation of ivermectin and mebendazole as low-toxicity, adjunctive cancer therapies.

Given the strength of the signal observed here, advancing this line of investigation is no longer optional—it is necessary.

This is NOT the end. We will continue advancing this work with larger datasets to further define and validate the role of anti-parasitics in cancer outcomes.

The manuscript is now available as a preprint on the Zenodo research repository, operated by the European Organization for Nuclear Research, while undergoing peer review at leading oncology journals: “Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort.”

Bar chart showing distribution of common cancer types with breast cancer most prevalent.
Infographic on disease status and median duration since diagnosis.

Receive Our Newsletter

13 + 3 =

jQuery( document ).ready(function( $ ) { // $( "div" ).hide(); });